Company · Public · BEAM
Beam Therapeutics
Precision genetic medicine company using base editing to make single-letter DNA changes without double-strand breaks.
EvidenceModerateProgramme on track
Listing
Public
Ticker
BEAM
Headquarters
Cambridge, US
Founded
2017
Technology
Base editing
Category
Market cap
$2.1B
Longevity thesis
Lower-risk editing chemistry broadens the set of diseases — and eventually risk genes — that can be safely addressed.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| BEAM-101 | Phase 1/2 | Sickle cell disease |
| BEAM-302 | Phase 1/2 | Alpha-1 antitrypsin deficiency |
Recent developments
- 30 Jun 2026Reported corrected protein levels in AATD patients.
Scientific evidence
EvidenceModerate
Early human efficacy in monogenic disease.
LONGEFI analysis
A technical bellwether: base editing safety data shape how regulators may later view preventive genetic intervention.
Analysis is research commentary. It is not investment advice or a recommendation.